Supports High Output Current in Combination with an External Power Transistor

TOKYO - Tuesday, March 25th 2014 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) today announced the launch of "TB9005FNG”, a 5-volt constant voltage regulator for application in automotive systems. Sample shipments start today, with mass production scheduled to start in December 2014.

"TB9005FNG” supports 1A or higher output current in combination with external power transistors1, allowing use in automotive applications that require high output current. The IC also incorporates system reset functions for reset of microcontrollers when their voltage is lowered or clock signals are cut off, which contributes to improved safety for automotive systems.

Applications

Automotive applications using 5-volt microcontrollers

Key Features

Part Number
          

TB9005FNG

Output Voltage
   &n ... Read more »

i2c's global platform provides bank with advanced card processing and mobile capabilities

REDWOOD CITY, Calif - Tuesday, March 25th 2014 [ME NewsWire]

(BUSINESS WIRE)-- i2c, Inc., a provider of payment processing and emerging commerce solutions, today announced that Caledonian Bank Ltd., a division of Caledonian Global Financial Services Inc., is leveraging its global platform for next-generation card processing.

Founded in 1970, Caledonian provides high net worth individuals and corporations around the world with a full range of financial services, including banking, brokerage, wealth management and asset protection services. It was named Best Private Bank in 2013 by World Finance and Best Offshore Bank by Global Financial Review.

"Caledonian is guided by a set of core values – Integrity, Excellence and Leadership – which factored into our choice of payment processor. We chose i2c because they will be a partner in helping us uphold these values,” said Ellj ... Read more »

ME Newswire / Business Wire

SUMMIT, N.J - Monday, March 24th 2014

OTEZLA demonstrated stable improvements in PASI response up to week 52 in ESTEEM 1 OTEZLA significantly improved signs and symptoms of psoriasis, including scalp and nails, compared with placebo in ESTEEM 2 at week 16, consistent with previously-reported ESTEEM 1 data Long term safety and tolerability profile in ESTEEM 1 was consistent with previously-reported long-term data from OTEZLA clinical trial programs No clinically meaningful changes in laboratory measurements compared with placebo observed in ESTEEM 1 or 2

Celgene Corporation (NASDAQ:CELG) today released new research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.

In ESTEEM 1 and ... Read more »

SHENZHEN, China - Monday, March 24th 2014 [ME NewsWire]

(BUSINESS WIRE)-- Aeronautical Radio of Thailand Limited, a state enterprise under the Ministry of Transport and Communications of Thailand, recently announced that Hytera Communications Co., Ltd has won the contract to supply TETRA radios for Suvarnabhumi and Don Muang Airport in Bangkok, Thailand.

Aeronautical Radio of Thailand Limited (AEROTHAI), founded in 1948 by airlines with the consent of the Royal Thai Government, aims to provide air traffic control and aeronautical communication services for airline operations. AEROTHAI built an integrated TETRA system network covering Bangkok International Airports since 2007, and it was used by the ground crews and logistic company for daily operational communications.

Provided by AEROTHAI, Suvarnabhumi and Don Muang Airport in Bangkok, Thailand, among the top 15 busiest airports in the world, have been using Hytera TETRA radios since April 2013 for trial. The use ... Read more »

WASHINGTON - Monday, March 24th 2014 [ME NewsWire]

 (BUSINESS WIRE)--- In a quarterly meeting March 20, the Overseas Private Investment Corporation’s (OPIC) Board of Directors approved two framework agreements that will align OPIC with Citi, the leading global bank, in sharing credit risk for development financing in overseas projects. The global risk-sharing frameworks cover both commercial lending and a new inclusive finance facility.

The two agreements provide OPIC’s guarantee of loans made by Citi to borrowers in OPIC-eligible countries around the world. Beginning in 2003, Citi and OPIC developed a Risk Sharing Program wherein OPIC provides a comprehensive partial guarantee for loans originated and extended by Citi in the emerging markets. During a decade-plus partnership, Citi and OPIC have executed 16 different frameworks totaling $2.8 billion in guarantee capacity.

Loans previously guaranteed by OPIC through Citibank have supported large-scale developme ... Read more »

TOKYO - Tuesday, March 25th 2014 [ME NewsWire]

(BUSINESS WIRE)-- Shiseido Co., Ltd. (TOKYO:4911) has been selected and awarded the 2014 World’s Most Ethical Companies designation for the third consecutive year. The announcement was made on March 20, 2014 by Ethisphere® Institute, a U.S.-based international think-tank dedicated to advocating best practices in business in such areas as corporate ethics and corporate social responsibility (CSR).

In addition to strengthening governance and thoroughly adhering to sound corporate ethics, global companies are currently urged to address major management challenges by taking a leadership role concerning social and environmental issues while also ensuring profitable, sustainable growth. Shiseido considers that these consecutive awards indicate society’s evaluation for its initiatives toward "becoming a global player representing Asia with its origins in Japan”. Shiseido will not only promote management with even more transparen ... Read more »

INGELHEIM, Germany - Monday, March 24th 2014 [ME NewsWire]

(BUSINESS WIRE) For media outside of the US, the UK & Canada only

Boehringer Ingelheim has today announced that new findings from ongoing Pradaxa® (dabigatran etexilate) research will be presented during the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14) in Washington, USA, 29 – 31 March 2014. The data form part of Boehringer Ingelheim’s ongoing commitment to scientific innovation and advancing patient care.

Data from three separate company-sponsored Pradaxa®-related studies will be announced during the congress. The presentations will cover subgroup results from the pivotal RE-LY® trial, evaluating the use of Pradaxa® compared to warfarin in patients with atrial fibrillation and valvular heart disease*.1 An oral presentation will highlight new data from pre-clinical research into an investigational antidote for Pradaxa®.2 Furthermore, first data from GLORIA ... Read more »